Testing of NBIA Genes: Analysis of Genetic Heterogeneity and Validation of Mitochondrial Markers for Assessing Causality of Sequence Variants. (NBIA MITO)

Neurodegeneration with brain iron accumulation (NBIA) represent a group of rare neurodevelopmental diseases, genetically as well as phenotypically heterogeneous.

The diagnosis is based on brain MRI. It is also based on genetic testing. However overlaps exist between the different clinical presentations and the molecular diagnosis may be misinterpreted.

Two main purposes must be addressed to get a better molecular diagnosis: on one hand reaching enough exhaustivity which may be performed with a larger gene panel and next generation sequencing; on the other hand, it is now necessary to validate or infirm the deleterious consequences of variants with the help of functional studies.

Study Overview

• Status: Completed
• Conditions: Neurodegeneration With Brain Iron Accumulation (NBIA)
• Intervention / Treatment: Genetic: Sequencing tests; Genetic: Establishment of mitochondrial markers

Detailed Description

Neurodegeneration with brain iron accumulation (NBIA) represent a group of rare neurodevelopmental diseases, genetically as well as phenotypically heterogeneous.

The diagnosis is based on brain MRI. It shows abnormal deposit of iron in the basal ganglia, especially in the globus pallidus and the substance nigra. It is also based on genetic testing. Ten individualized forms are now described. However overlaps exist between the different clinical presentations and the molecular diagnosis may be misinterpreted because of variants, named as variants of unknown signification, whom the pathogenic role is not proven. Approximately half of the clinically relevant cases with iron deposits on brain MRI remain without any molecular deleterious alteration.

Two main purposes must be addressed to get a better molecular diagnosis: on one hand reaching enough exhaustivity which may be performed with a larger gene panel and next generation sequencing; this panel will include new genes and could be enlarged as more genes are identified. On the other hand, it is now necessary to validate or infirm the deleterious consequences of variants with the help of functional studies.

Four major pathways are involved in the pathophysiology of NBIA: iron and lipids metabolisms, mitochondrial metabolism and autophagy.

Considering that biochemical mechanisms inside the mitochodrion are involved in these four pathways, the investigators performed a first test starting from patient's fibroblasts and analyzed the literature in order to define the parameters that could be pertinent as biological markers of NBIA.

Two different groups will be studied :

• A group of NBIA patients without found mutation after sequencing of the gene panel currently used at the university hospital of Bordeaux. Genetic testing will be performed with the help of an alternative method of target enrichment applied to 16 NBIA genes.
• A group of patients with 2 frequent forms of NBIA with identified variants will be analysed to assess the best mitochondrial markers from fibroblasts.

The investigators plan to transfer these new genetic and biochemical strategies to the diagnostic procedures with the support of the french rare disease network in charge of neurodegenerations and the "CARAMMEL" network involved in the diagnosis of mitochondrial diseases.

• Study Type: Observational
• Enrollment (Actual): 70

Contacts and Locations

Study Locations

• France
  • Talence, France
    • Centre Hospitalier Universitaire De Bordeaux

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult; Older Adult
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

Patients with NBIA

Description

Inclusion Criteria:

• NBIA Patients diagnosed with a pathogenic variation or any variation that could impact gene function (class 4 or 5 according to ACMG criteria) in the following genes: C19ORF12, PANK2, PLA2G6, DCAF17, FA2H, WDR45, FTL, CP and ATP13A2 and whose fibroblasts have been collected at Bordeaux University Hospital for functional analysis during the diagnosis procedure
• NBIA patients without conclusive testing in none of these nine genes and whose DNA has been collected during the diagnosis procedure at Bordeaux University Hospital

Exclusion Criteria:

• Patients without imaging (MRI or scan) signs of NBIA
• Patients without french healthcare insurance

Study Plan

How is the study designed?

Design Details

• Observational Models: Cohort
• Time Perspectives: Retrospective

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Patients with NBIA who remain without molecular diagnosis; A group of 40 patients with NBIA, who remain without molecular diagnosis	Genetic: Sequencing tests; sequencing tests of a panel of 22 genes (9 already known and 13 new genes) using a dedicated custom capture and a medium throughput sequencing protocol.
Patients with NBIA with identified mutations in genes; A group of patients with 2 frequent forms of NBIA, carrying mutations in genes (already studied in the CHU molecular diagnostic laboratory)	Genetic: Establishment of mitochondrial markers; Establishment of mitochondrial markers from fibroblasts in culture, obtained from a skin biopsy. Establishment of yeast models to show biochemical mitochondrial alterations: introduction of missense variants in the pantothenate kinase yeast gene Cab1 whose deletion is lethal, followed by growth of mutant strains on fermentation and respiratory media.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Sequencing tests of a panel of 22 genes using a dedicated custom capture and a medium throughput sequencing protocol.	Records of coverage (% of designed regions)	through study completion, an average of 2 years
Sequencing tests of a panel of 22 genes using a dedicated custom capture and a medium throughput sequencing protocol.	Records of depth of sequencing (reads number)	through study completion, an average of 4 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Identification of the dominant form using biochemical analysis in patient's fibroblasts	Counting of mitochondria with Voltage-dependent anion channel (VDAC) labeling	through study completion, an average of 2 years
Identification of the dominant form using biochemical analysis in patient's fibroblasts	Measurements of iron and ferritin cellular levels after iron deprivation and iron loading	through study completion, an average of 2 years

Collaborators and Investigators

• Sponsor: University Hospital, Bordeaux
• Collaborators: Institut National de la Santé Et de la Recherche Médicale, France
• Investigators: Principal Investigator: Patricia FERGELOT MAURIN, University Hospital, Bordeaux

Study record dates

Study Major Dates

• Study Start (Actual): January 4, 2018
• Primary Completion (Actual): November 30, 2020
• Study Completion (Actual): November 30, 2020

Study Registration Dates

• First Submitted: July 1, 2021
• First Submitted That Met QC Criteria: November 7, 2022
• First Posted (Actual): November 14, 2022

Study Record Updates

• Last Update Posted (Actual): November 14, 2022
• Last Update Submitted That Met QC Criteria: November 7, 2022
• Last Verified: September 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Genetic Diseases, Inborn; Basal Ganglia Diseases; Movement Disorders; Neurodegenerative Diseases; Heredodegenerative Disorders, Nervous System; Neuroaxonal Dystrophies; Pantothenate Kinase-Associated Neurodegeneration; Nerve Degeneration
• Other Study ID Numbers: CHUBX 2017/38

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No